Arivazhagan Srinivasan, Lamech Tanuj Moses, Myvizhiselvi Murugan, Arumugam Venkatesh, Alavudeen Sheik Sulthan, Dakshinamoorthy Shivakumar, Dineshkumar Thanigachalam, Sakthirajan Ramanathan, Dhanapriya Jeyachandran, Shankar Palaniselvam, Padmaraj Rajendran, Kurien Anila Abraham, Gopalakrishnan Natarajan
Institute of Nephrology, Madras Medical College, Chennai, India.
Renopath Center for Renal and Urological Pathology, Chennai, India.
Kidney Int Rep. 2022 Aug 4;7(10):2160-2165. doi: 10.1016/j.ekir.2022.07.163. eCollection 2022 Oct.
Infection-related glomerulonephritis (IRGN) is associated with glomerular immune complex deposition along with complement activation. Steroids may attenuate glomerular injury and thereby improve renal outcomes.
We randomly assigned patients who had biopsy-proven IRGN and serum creatinine greater than 1.5 mg/dl to receive corticosteroids plus supportive care (intervention arm), or supportive care alone (control arm). Patients were followed up for 6 months. The primary outcome was complete renal recovery at 6 months. Safety of steroid therapy was also assessed.
A total of 52 patients underwent randomization. At 6 months, 17 of 26 patients (65.4%) in the intervention arm and 14 of 26 patients (53.8%) in the control arm had complete renal recovery (odds ratio 1.6; 95% confidence interval, 0.5-4.9; = 0.397). There was no statistically significant difference in any of the secondary outcomes. Adverse events occurred in 12 patients (46.2%) in the intervention arm and 2 patients (7.7%) in the control arm ( = 0.002).
In this single-center trial, corticosteroids did not result in a statistically significant increase in rates of complete renal recovery at 6 months. There was a significantly increased risk of adverse events associated with the use of corticosteroids.
感染相关性肾小球肾炎(IRGN)与肾小球免疫复合物沉积以及补体激活有关。类固醇可能减轻肾小球损伤,从而改善肾脏预后。
我们将经活检证实为IRGN且血清肌酐大于1.5mg/dl的患者随机分为两组,一组接受皮质类固醇加支持治疗(干预组),另一组仅接受支持治疗(对照组)。对患者进行6个月的随访。主要结局是6个月时完全肾脏恢复。还评估了类固醇治疗的安全性。
共有52例患者进行了随机分组。6个月时,干预组26例患者中有17例(65.4%)完全肾脏恢复,对照组26例患者中有14例(53.8%)完全肾脏恢复(优势比1.6;95%置信区间,0.5 - 4.9;P = 0.397)。任何次要结局均无统计学显著差异。干预组有12例患者(46.2%)发生不良事件,对照组有2例患者(7.7%)发生不良事件(P = 0.002)。
在这项单中心试验中,皮质类固醇在6个月时并未使完全肾脏恢复率有统计学显著提高。使用皮质类固醇与不良事件风险显著增加相关。